Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer
First results for Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC in this setting reported from…